Diaz-delCastillo M., Andrews R.E., Mandal A., Andersen T.L., Chantry A.D., Heegaard A.M. Bone Pain in Multiple Myeloma (BPMM)-A Protocol for a Prospective, Longitudinal, Observational Study. Cancers (Basel). 2021;13(7):1596. https://doi.org/10.3390/cancers13071596..
DOI: 10.3390/cancers13071596
Moreau P., Attal M., Caillot D., Macro M., Karlin L., Garderet L. et al. Prospective Evaluation of Magnetic Resonance Imaging and [18F] Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017;35(25):2911–2918. https://doi.org/10.1200/JCO.2017.72.2975..
DOI: 10.1200/JCO.2017.72.2975
Mateos M.V., Fink L., Koneswaran N., Intorcia M., Giannopoulou C., Niepel D., Cavo M. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. BMC Cancer. 2020;20(1):170. https://doi.org/10.1186/s12885-020-6596-y..
DOI: 10.1186/s12885-020-6596-y
Nahi H., Chrobok M., Gran C., Lund J., Gruber A., Gahrton G. et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS ONE. 2019;14(2):e0211927. https://doi.org/10.1371/journal.pone.0211927..
DOI: 10.1371/journal.pone.0211927
Chanan-Khan A., Sonneveld P., Schuster M.W., Stadtmauer E.A., Facon T., Harousseau J.L. et al. Analysis of herpes zoster events among bortezomibtreated patients in the phase III APEX study. J Clin Oncol. 2008;26(29):4784–4790. https://doi.org/10.1200/JCO.2007.14.9641..
DOI: 10.1200/JCO.2007.14.9641
Vassilopoulos S., Vassilopoulos A., Kalligeros M., Shehadeh F., Mylonakis E. Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis. Open Forum Infect Dis. 2022;9(11):ofac574. https://doi.org/10.1093/ofid/ofac574..
DOI: 10.1093/ofid/ofac574
Семочкин С.В., Соловьев М.В., Менделеева Л.П. Профилактика и лечение бортезомибиндуцированной нейропатии у пациентов с множественной миеломой. Онкогематология. 2022;17(2):141–150. https://doi.org/10.17650/1818-8346-2022-17-2-141-150..
DOI: 10.17650/1818-8346-2022-17-2-141-150
Panaroni C., Yee A.J., Raje N.S. Myeloma and Bone Disease. Curr Osteoporos Rep. 2017;15(5):483–498. https://doi.org/10.1007/s11914-017-0397-5..
DOI: 10.1007/s11914-017-0397-5
Kim J.M., Lin C., Stavre Z., Greenblatt M.B., Shim J.H. Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. 2020;9(9):2073. https://doi.org/10.3390/cells9092073..
DOI: 10.3390/cells9092073
Nencini S., Ivanusic J.J. The Physiology of Bone Pain. How Much Do We Really Know? Front Physiol. 2016;7:157. https://doi.org/10.3389/fphys.2016.00157..
DOI: 10.3389/fphys.2016.00157
Yoneda T., Hiasa M., Okui T. Crosstalk Between Sensory Nerves and Cancer in Bone. Curr Osteoporos Rep. 2018;16(6):648–656. https://doi.org/10.1007/s11914-018-0489-x..
DOI: 10.1007/s11914-018-0489-x
Choi S.J., Oba Y., Gazitt Y., Alsina M., Cruz J., Anderson J., Roodman G.D. Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease. J Clin Invest. 2001;108(12):1833–1841. https://doi.org/10.1172/JCI13116..
DOI: 10.1172/JCI13116
Oshima T., Abe M., Asano J., Hara T., Kitazoe K., Sekimoto E. et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005;106(9):3160–3165. https://doi.org/10.1182/blood-2004-12-4940..
DOI: 10.1182/blood-2004-12-4940
Edwards C.M., Edwards J.R., Lwin S.T., Esparza J., Oyajobi B.O., McCluskey B. et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood. 2008;111(5):2833–2842. https://doi.org/10.1182/blood-2007-03-077685..
DOI: 10.1182/blood-2007-03-077685
Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J.D.Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109(5):2106–2111. https://doi.org/10.1182/blood-2006-09-047712..
DOI: 10.1182/blood-2006-09-047712
Wang J.H., Zhang Y., Li H.Y., Liu Y.Y., Sun T. Dickkopf-1 negatively regulates the expression of osteoprotegerin, a key osteoclastogenesis inhibitor, by sequestering Lrp6 in primary and metastatic lytic bone lesions. Medicine (Baltimore). 2016;95(24):e3767. https://doi.org/10.1097/MD.0000000000003767..
DOI: 10.1097/MD.0000000000003767
Hiasa M., Okui T., Allette Y.M., Ripsch M.S., Sun-Wada G.H., Wakabayashi H. et al. Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3. Cancer Res. 2017;77(6):1283–1295. https://doi.org/10.1158/0008-5472.CAN-15-3545..
DOI: 10.1158/0008-5472.CAN-15-3545
Nencini S., Ivanusic J. Mechanically sensitive Aδ nociceptors that innervate bone marrow respond to changes in intra-osseous pressure. J Physiol. 2017;595(13):4399–4415. https://doi.org/10.1113/jp273877..
DOI: 10.1113/jp273877
Castañeda-Corral G., Jimenez-Andrade J.M., Bloom A.P., Taylor R.N., Mantyh W.G., Kaczmarska M.J. et al. The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience. 2011;178:196–207. https://doi.org/10.1016/j.neuroscience.2011.01.039..
DOI: 10.1016/j.neuroscience.2011.01.039
Tando T., Sato Y., Miyamoto K., Morita M., Kobayashi T., Funayama A. et al. Hif1α is required for osteoclast activation and bone loss in male osteoporosis. Biochem Biophys Res Commun. 2016;470(2):391–396. https://doi.org/10.1016/j.bbrc.2016.01.033..
DOI: 10.1016/j.bbrc.2016.01.033
Terpos E., Zamagni E., Lentzsch S., Drake M.T., García-Sanz R., Abildgaard N. et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e119–e130. https://doi.org/10.1016/S1470-2045(20)30559-3..
DOI: 10.1016/S1470-2045(20)30559-3
Morgan G.J., Child J.A., Gregory W.M., Szubert A.J., Cocks K., Bell S.E. et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011;12(8):743–752. https://doi.org/10.1016/S1470-2045(11)70157-7..
DOI: 10.1016/S1470-2045(11)70157-7
Perazella M.A., Markowitz G.S. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385–1393. https://doi.org/10.1038/ki.2008.356..
DOI: 10.1038/ki.2008.356
Gimsing P., Carlson K., Turesson I., Fayers P., Waage A., Vangsted A. et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 2010;11(10):973–982. https://doi.org/10.1016/S1470-2045(10)70198-4..
DOI: 10.1016/S1470-2045(10)70198-4
Coleman R., Hadji P., Body J.J., Santini D., Chow E., Terpos E. et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650–1663. https://doi.org/10.1016/j.annonc.2020.07.019..
DOI: 10.1016/j.annonc.2020.07.019
Raje N., Vescio R., Montgomery C.W., Badros A., Munshi N., Orlowski R. et al. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clin Cancer Res. 2016;22(6):1378–1384. https://doi.org/10.1158/1078-0432.CCR-15-1864..
DOI: 10.1158/1078-0432.CCR-15-1864
Royle K.L., Gregory W.M., Cairns D.A., Bell S.E., Cook G., Owen R.G. et al. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. Br J Haematol. 2018;182(6):816–829. https://doi.org/10.1111/bjh.15459..
DOI: 10.1111/bjh.15459
Raje N., Terpos E., Willenbacher W., Shimizu K., García-Sanz R., Durie B. et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370–381. https://doi.org/10.1016/S1470-2045(18)30072-X..
DOI: 10.1016/S1470-2045(18)30072-X
Kunizawa K., Hiramatsu R., Hoshino J., Mizuno H., Ozawa Y., Sekine A. et al. Denosumab for dialysis patients with osteoporosis: A cohort study. Sci Rep. 2020;10(1):2496. https://doi.org/10.1038/s41598-020-59143-8..
DOI: 10.1038/s41598-020-59143-8
Meredith R.F., Bassler J.R.., McDonald A.M., Stahl J.M., Redden D.T., Bonner J.A. Biological Effective Radiation Dose for Multiple Myeloma Palliation. Adv Radiat Oncol. 2023;8(4):101214. https://doi.org/10.1016/j.adro.2023.101214..
DOI: 10.1016/j.adro.2023.101214
Rades D., Conde-Moreno A.J., Cacicedo J., Segedin B., Rudat V., Schild S.E. Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma. Radiol Oncol. 2016;50(3):337–340. Available at: https://pubmed.ncbi.nlm.nih.gov/27679551.https://pubmed.ncbi.nlm.nih.gov/27679551
Rades D., Conde-Moreno A.J., Cacicedo J., Segedin B., Rudat V., Schild S.E. Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma. Radiol Oncol. 2016;50(3):337–340. Available at: https://pubmed.ncbi.nlm.nih.gov/27679551.https://pubmed.ncbi.nlm.nih.gov/27679551
Rudzianskiene M., Inciura A., Gerbutavicius R., Rudzianskas V., Macas A., Simoliuniene R. et al. Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma: A prospective randomized study. Strahlenther Onkol. 2017;193(9):742–749. https://doi.org/10.1007/s00066-017-1154-5..
DOI: 10.1007/s00066-017-1154-5
Fabregat C., Almendros S., Navarro-Martin A., Gonzalez J. Pain Flare-Effect Prophylaxis With Corticosteroids on Bone Radiotherapy Treatment: A Systematic Review. Pain Pract. 2020;20(1):101–109. https://doi.org/10.1111/papr.12823..
DOI: 10.1111/papr.12823
Валиев А.К., Соколовский А.В., Неред А.С., Мусаев Э.Р. Малоинвазивные хирургические технологии при поражениях позвоночника в онкогематологии. Клиническая онкогематология. 2013;(2):177–194. Режим доступа: https://bloodjournal.ru/wp-content/uploads/2015/11/6-Stranitsy-izOnco_2_2013_-6.pdfhttps://bloodjournal.ru/wp-content/uploads/2015/11/6-Stranitsy-izOnco_2_2013_-6.pdf
Валиев А.К., Соколовский А.В., Неред А.С., Мусаев Э.Р. Малоинвазивные хирургические технологии при поражениях позвоночника в онкогематологии. Клиническая онкогематология. 2013;(2):177–194. Режим доступа: https://bloodjournal.ru/wp-content/uploads/2015/11/6-Stranitsy-izOnco_2_2013_-6.pdfhttps://bloodjournal.ru/wp-content/uploads/2015/11/6-Stranitsy-izOnco_2_2013_-6.pdf
Eseonu K.C., Panchmatia J.R., Streetly M.J., Grauer J.N., Fakouri B. The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma. Hematol Oncol. 2022;10.1002/hon.3102. https://doi.org/10.1002/hon.3102..
DOI: 10.1002/hon.3102
Fallon M., Giusti R., Aielli F., Hoskin P., Rolke R., Sharma M., Ripamonti C.I. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv166–iv191. https://doi.org/10.1093/annonc/mdy152..
DOI: 10.1093/annonc/mdy152
Семочкин С.В. Новые ингибиторы протеасомы в терапии множественной миеломы. Онкогематология. 2019;14(2):29–40. https://doi.org/10.17650/1818-8346-2019-14-2-29-40..
DOI: 10.17650/1818-8346-2019-14-2-29-40
Ohashi Y., Yatabe M., Niijima D., Imamura A., Nagayama Y., Otsuka K. et al. Importance of Compliance With Guidelines for the Prevention of VaricellaZoster Virus Reactivation in Multiple Myeloma. In Vivo. 2021;35(6):3289–3296. https://doi.org/10.21873/invivo.12624..
DOI: 10.21873/invivo.12624
Henze L., Buhl C., Sandherr M., Cornely O.A., Heinz W.J., Khodamoradi Y. et al. Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. Ann Hematol. 2022;101(3):491–511. https://doi.org/10.1007/s00277-021-04746-y..
DOI: 10.1007/s00277-021-04746-y
Strasfeld L., Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010;24(3):809–833. https://doi.org/10.1016/j.idc.2010.07.001..
DOI: 10.1016/j.idc.2010.07.001
Finnerup N.B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R.H. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. https://doi.org/10.1016/S1474-4422(14)70251-0..
DOI: 10.1016/S1474-4422(14)70251-0
Derry S., Rice A.S., Cole P., Tan T., Moore R.A. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;1(1):CD007393. https://doi.org/10.1002/14651858.CD007393.pub4..
DOI: 10.1002/14651858.CD007393.pub4
Stubblefield M.D., Burstein H.J., Burton A.W., Custodio C.M., Deng G.E., Ho M. et al. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7(5):1–26. https://doi.org/10.6004/jnccn.2009.0078..
DOI: 10.6004/jnccn.2009.0078
Selvy M., Kerckhove N., Pereira B., Barreau F., Nguyen D., Busserolles J. et al. Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center CrossSectional Study. Front Pharmacol. 2021;12:637593. https://doi.org/10.3389/fphar.2021.637593..
DOI: 10.3389/fphar.2021.637593
Richardson P.G., Sonneveld P., Schuster M.W., Stadtmauer E.A., Facon T., Harousseau J.L. et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895–903. https://doi.org/10.1111/j.1365-2141.2008.07573.x..
DOI: 10.1111/j.1365-2141.2008.07573.x
Arnulf B., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., van de Velde H. et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925–1928. https://doi.org/10.3324/haematol.2012.067793..
DOI: 10.3324/haematol.2012.067793
Dimopoulos M.A., Moreau P., Palumbo A., Joshua D., Pour L., Hájek R. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38. https://doi.org/10.1016/S1470-2045(15)00464-7..
DOI: 10.1016/S1470-2045(15)00464-7
Yan W., Wu Z., Zhang Y., Hong D., Dong X., Liu L. et al. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy. Biomed Pharmacother. 2021;142:112068. https://doi.org/10.1016/j.biopha.2021.112068..
DOI: 10.1016/j.biopha.2021.112068
Li Y., Lustberg M.B., Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of ChemotherapyInduced Peripheral Neuropathy. Cancers (Basel). 2021;13(4):766. https://doi.org/10.3390/cancers13040766..
DOI: 10.3390/cancers13040766
Geyer H.L., Gazelka H., Mesa R. How I treat pain in hematologic malignancies safely with opioid therapy. Blood. 2020;135(26):2354–2364. https://doi.org/10.1182/blood.2019003116..
DOI: 10.1182/blood.2019003116
Chou R., Turner J.A., Devine E.B., Hansen R.N., Sullivan S.D., Blazina I. et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–286. https://doi.org/10.7326/m14-2559..
DOI: 10.7326/m14-2559
Lee M., Silverman S.M., Hansen H., Patel V.B., Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–161. Available at: https://pubmed.ncbi.nlm.nih.gov/21412369.https://pubmed.ncbi.nlm.nih.gov/21412369
Lee M., Silverman S.M., Hansen H., Patel V.B., Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–161. Available at: https://pubmed.ncbi.nlm.nih.gov/21412369.https://pubmed.ncbi.nlm.nih.gov/21412369
Klimas J., Gorfinkel L., Fairbairn N., Amato L., Ahamad K., Nolan S. et al. Strategies to Identify Patient Risks of Prescription Opioid Addiction When Initiating Opioids for Pain: A Systematic Review. JAMA Netw Open. 2019;2(5):e193365. https://doi.org/10.1001/jamanetworkopen.2019.3365..
DOI: 10.1001/jamanetworkopen.2019.3365
Corder G., Castro D.C., Bruchas M.R., Scherrer G. Endogenous and Exogenous Opioids in Pain. Annu Rev Neurosci. 2018;41:453–473. https://doi.org/10.1146/annurev-neuro-080317-061522..
DOI: 10.1146/annurev-neuro-080317-061522
Schol J., Wauters L., Dickman R., Drug V., Mulak A., Serra J. et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European Gastroenterol J. 2021;9(3):287–306. https://doi.org/10.1002/ueg2.12060..
DOI: 10.1002/ueg2.12060
Meissner W., Leyendecker P., Mueller-Lissner S., Nadstawek J., Hopp M., Ruckes C. et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56–64. https://doi.org/10.1016/j.ejpain.2008.06.012..
DOI: 10.1016/j.ejpain.2008.06.012
Coluzzi F., Scerpa M.S., Centanni M. The Effect of Opiates on Bone Formation and Bone Healing. Curr Osteoporos Rep. 2020;18(3):325–335. https://doi.org/10.1007/s11914-020-00585-4..
DOI: 10.1007/s11914-020-00585-4
Coluzzi F., Rolke R., Mercadante S. Pain Management in Patients with Multiple Myeloma: An Update. Cancers (Basel). 2019;11(12):2037. https://doi.org/10.3390/cancers11122037..
DOI: 10.3390/cancers11122037
Nguyen J., Luk K., Vang D., Soto W., Vincent L., Robiner S. et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br J Anaesth. 2014;113(Suppl. 1):i4–i13. https://doi.org/10.1093/bja/aeu090..
DOI: 10.1093/bja/aeu090
Haque M.R., Barlass U., Armstrong A., Shaikh M., Bishehsari F. Novel role of the Mu-opioid receptor in pancreatic cancer: potential link between opioid use and cancer progression. Mol Cell Biochem. 2022;477(5):1339–1345.https://doi.org/10.1007/s11010-022-04377-5..
DOI: 10.1007/s11010-022-04377-5
Cata J.P., Keerty V., Keerty D., Feng L., Norman P.H., Gottumukkala V. et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014;3(4):900–908. https://doi.org/10.1002/cam4.236..
DOI: 10.1002/cam4.236
Exadaktylos A.K., Buggy D.J., Moriarty D.C., Mascha E., Sessler D.I. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105(4):660–604. https://doi.org/10.1097/00000542-200610000-00008..
DOI: 10.1097/00000542-200610000-00008
Cao L.H., Li H.T., Lin W.Q., Tan H.Y., Xie L., Zhong Z.J., Zhou J.H. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep. 2016;6:18706. https://doi.org/10.1038/srep18706..
DOI: 10.1038/srep18706
Bhoir S., Uhelski M., Guerra-Londono J.J., Cata J.P. The Role of Opioid Receptors in Cancer. Adv Biol (Weinh). 2023;e2300102. https://doi.org/10.1002/adbi.202300102..
DOI: 10.1002/adbi.202300102
Фирсова М.В., Менделеева Л.П., Соловьев М.В., Рехтина И.Г., Покровская О.С., Урнова Е.С. и др. Трансплантация аутологичных стволовых клеток крови больным множественной миеломой, осложненной диализ-зависимой почечной недостаточностью. Терапевтический архив. 2020;92(7):70–76. https://doi.org/10.26442/00403660.2020.07.000777..
DOI: 10.26442/00403660.2020.07.000777
Sweiss K., Hofmeister C.C., Quigley J.G., Sweis J.G., Kurzweil K., Sborov D.W. et al. Chronic Opioid Use Is Highly Prevalent and Associated with Inferior Survival in Myeloma Patients in Remission after Autologous Transplant. Blood. 2022;140(Suppl. 1):5252–5253. https://doi.org/10.1182/blood-2022-171045..
DOI: 10.1182/blood-2022-171045
Danish M.L., Shah M.R., Lin Y., Ho J.K., Copeland T.M., Cooper D.L. Persistent opioid use in patients with multiple myeloma post-ASCT. Eur J Haematol. 2022;108(6):503–509. https://doi.org/10.1111/ejh.13759..
DOI: 10.1111/ejh.13759
Семочкин С.В., Желнова Е.И., Мисюрина Е.Н., Марьин Д.С., Ушакова А.И., Каримова Е.А. и др. Клиническое значение восстановления функции почек у больных с впервые диагностированной множественной миеломой, осложненной тяжелой и диализ-зависимой почечной недостаточностью. Гематология и трансфузиология. 2019;64(3):283–296. https://doi.org/10.35754/0234-5730-2019-64-3-283-296..
DOI: 10.35754/0234-5730-2019-64-3-283-296
Coluzzi F. Assessing and Treating Chronic Pain in Patients with End-Stage Renal Disease. Drugs. 2018;78(14):1459–1479. https://doi.org/10.1007/s40265-018-0980-9..
DOI: 10.1007/s40265-018-0980-9
Coluzzi F., Raffa R.B., Pergolizzi J., Rocco A., Locarini P., Cenfra N. et al. Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res. 2015;8:229–238. https://doi.org/10.2147/JPR.S83490..
DOI: 10.2147/JPR.S83490
Moreau P., Karamanesht I.I., Domnikova N., Kyselyova M.Y., Vilchevska K.V., Doronin V.A. et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51(12):823–829. https://doi.org/10.1007/s40262-012-0010-0..
DOI: 10.1007/s40262-012-0010-0
Gupta N., Hanley M.J., Xia C., Labotka R., Harvey R.D., Venkatakrishnan K. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clin Pharmacokinet. 2019;58(4):431–449. https://doi.org/10.1007/s40262-018-0702-1..
DOI: 10.1007/s40262-018-0702-1
Kasserra C., Assaf M., Hoffmann M., Li Y., Liu L., Wang X. et al. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol. 2015;55(2):168–178. https://doi.org/10.1002/jcph.384..
DOI: 10.1002/jcph.384
Tennant F. Opioid regimens in patients with chronic pain with multiple cytochrome P450 defects. J Opioid Manag. 2015;11(3):237–242. https://doi.org/10.5055/jom.2015.0272..
DOI: 10.5055/jom.2015.0272
Абузарова Г.Р., Косоруков В.С., Гамзелева О.Ю., Сарманаева Р.Р., Бражникова Ю.В. Эффективность и безопасность препарата Тафалгин у пациентов с онкологической болью. Результаты открытого сравнительного многоцентрового рандомизированного клинического исследования. Онкология. Журнал им. П.А. Герцена. 2022;11(5):38–48. https://doi.org/10.17116/onkolog20221105138..
DOI: 10.17116/onkolog20221105138